ClinicalTrials.gg
CompletedNCT03237325Updated Nov 8, 2022Results posted

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

A Phase 3 interventional study of SGX942 and Placebo in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx and Oral Mucositis, sponsored by Soligenix. Completed at 53 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Soligenix · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
91st of 994
266 · median 41
Started
2017
with 48 others
Phase 3
71 of 1,099
12 open now
Registered
491st of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 91st largest by enrollment of the 994 interventional ones that give a count, is one of 49 that started in 2017, is one of 71 in phase 3, and was the 491st registered.

Squamous Cell Carcinoma of Head and Neck

2,022 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer

03

Conditions studied

  • Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
  • Oral Mucositis

Keywords

  • OM
  • Head and Neck Cancer
  • SGX942
  • Dusquetide
  • Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven squamous cell carcinoma of the oral cavity or oropharynx without distant organ
  • Scheduled to receive cisplatin chemotherapy of 80-100 mg/m²
  • Scheduled to receive a continuous course of fractionated, conventional external beam with a cumulative radiation dose between 55 and 72 Gy at each site

Exclusion criteria

Exclusion Criteria:

  • Current mucositis
  • Current, , active infection that in the opinion of the Investigator would make them an unfit participant in the trial
  • Planned to receive Erbitux™ (Cetuximab) or similar targeted therapy between Baseline and 6 weeks post-RT
  • Prior radiation to the head and neck
  • Chemotherapy treatment within the previous 12 months
  • Tumors of the lips, sinuses, salivary glands, nasopharynx, hypopharynx, or larynx
  • Evidence of significant renal, hepatic, hematologic, or immunologic disease determined by any one of the following: Estimated \<30 mL/min; or AST level greater than 10-fold the or total greater than 3-fold the upper limit of normal; Manifestations of end-stage liver disease, such as ascites or hepatic encephalopathy; Thrombocytopenia; or below 200 cells per μL
  • Evidence of immediate life-threatening disease or a of less than 3 months
  • Women who are pregnant or breast-feeding
  • Participation in any study involving administration of an agent within 30 days of randomization into this study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    SGX942

    Patients are randomized 1:1 active/placebo.

    Drug: SGX942

  • Placebo comparator
    Placebo

    Patients are randomized 1:1 active/placebo.

    Drug: Placebo

Interventions

  • DrugDusquetideStudies of DusquetideDusquetide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.

    Also known as: Dusquetide

  • DrugPlacebo

    Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.

06

What researchers measure

Primary outcomes

  1. Duration of Severe Oral Mucositis (SOM)

    To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis (SOM; defined as World Health Organization \[WHO\] Grade ≥3). Duration of SOM is defined as the number of days from the onset of SOM until resolution of SOM. OM is evaluated using the published WHO OM grading scale that uses a scale of 0 to 4, with SOM defined as a score ≥3.

    Time frame: approx. 13 weeks

07

Results

Posted Aug 29, 2022

Participant flow

Participant flow — Overall Study
MilestoneSGX942Placebo
Started127139
Completed112114
Not completed1525
Withdrew: Lost to follow-up35
Withdrew: Physician decision24
Withdrew: Withdrawal by subject912
Withdrew: Noncompliance with study procedures11
Withdrew: Termination by sponsor01
Withdrew: Reason other than described02

Outcome measures

PrimaryDuration of Severe Oral Mucositis (SOM)

To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis (SOM; defined as World Health Organization \[WHO\] Grade ≥3). Duration of SOM is defined as the number of days from the onset of SOM until resolution of SOM. OM is evaluated using the published WHO OM grading scale that uses a scale of 0 to 4, with SOM defined as a score ≥3.

Time frame:
approx. 13 weeks
Reported as:
Median · days
Duration of Severe Oral Mucositis (SOM)
daysSGX942Placebo
Duration of Severe Oral Mucositis (SOM)12.5 (4.0 to 22.0)20.0 (12.0 to 29.0)
Statistical analysis
  • SGX942 vs Placebo · Log Rank · p = 0.1798

Adverse events

Collected over Adverse event (AE) data was collected between randomization through 6 weeks after radiation therapy treatment ended. Participants received up to 7 weeks of radiation, for a maximum AE collection time of 13 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SGX9427/127 (5.5%)74/127 (58.3%)123/127 (96.9%)
Placebo9/139 (6.5%)64/139 (46%)135/139 (97.1%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventSGX942Placebo
Acute kidney injuryRenal and urinary disorders12/1278/139
DehydrationMetabolism and nutrition disorders7/1274/139
DysphagiaGastrointestinal disorders5/1275/139
PyrexiaGeneral disorders5/1273/139
VomitingGastrointestinal disorders4/1272/139
EmbolismVascular disorders4/1270/139
NauseaGastrointestinal disorders3/1274/139
Febrile neutropeniaBlood and lymphatic system disorders3/1272/139
SepsisInfections and infestations3/1271/139
ConstipationGastrointestinal disorders2/1273/139
Most frequent other events
Showing 10 of 62
Most frequent other events
EventSGX942Placebo
NauseaGastrointestinal disorders88/12797/139
ConstipationGastrointestinal disorders71/12766/139
Dry mouthGastrointestinal disorders61/12768/139
FatigueGeneral disorders57/12764/139
DysgeusiaNervous system disorders58/12761/139
DysphagiaGastrointestinal disorders55/12760/139
VomitingGastrointestinal disorders43/12757/139
Radiation skin injuryInjury, poisoning and procedural complications46/12755/139
Oropharyngeal painRespiratory, thoracic and mediastinal disorders40/12744/139
Decreased appetiteMetabolism and nutrition disorders38/12743/139

Baseline characteristics

The baseline analysis population was defined as all participants that were treated with at least one dose of treatment (SGX942 or Placebo)

Age, Continuous
Age, Continuous(years)SGX942PlaceboTotal
Mean57.2 ± 7.4858.8 ± 8.7458.1 ± 8.19
Sex: Female, Male
Sex: Female, Male(Participants)SGX942PlaceboTotal
Female222850
Male105111216
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SGX942PlaceboTotal
Hispanic or Latino91524
Not Hispanic or Latino105113218
Unknown or Not Reported131124
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SGX942PlaceboTotal
American Indian or Alaska Native213
Asian134
Native Hawaiian or Other Pacific Islander000
Black or African American5611
White118128246
More than one race000
Unknown or Not Reported112
HPV Status
HPV Status(Participants)SGX942PlaceboTotal
Positive9392185
Negative344781
08

Study locations

53 sites
  • Arizona Clinical Research Center
    Tucson, Arizona 85715, United States
  • Loma Linda University Health
    Loma Linda, California 92354, United States
  • Pomona Valley Hospital Medical Center
    Pomona, California 91767, United States
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
  • Lakes Research
    Miami Lakes, Florida 33014, United States
  • University Cancer & Blood
    Athens, Georgia 30607, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Memorial Health
    Savannah, Georgia 31404, United States
  • University of Illinois Cancer Center
    Chicago, Illinois 60612, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Des Moines Oncology Research Association
    Des Moines, Iowa 50309, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Ashland Bellefonte Cancer Center
    Ashland, Kentucky 41101, United States
  • Willis Knighton Cancer Center
    Shreveport, Louisiana 71103, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Minnesota Oncology
    Saint Louis Park, Minnesota 55416, United States
  • University of Missouri-Ellis Fischel Cancer Center
    Columbia, Missouri 65203, United States
  • Great Falls Clinic
    Great Falls, Montana 59405, United States
  • CHI Health St. Francis
    Grand Island, Nebraska 68803, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89052, United States
  • Nevada Cancer Research Foundation
    Las Vegas, Nevada 89106, United States
  • Hackensack Meridian Health
    Neptune, New Jersey 07753, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Summa Health Cancer Research
    Akron, Ohio 44304, United States
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Mercy Clinic Oncology and Hematology
    Oklahoma City, Oklahoma 73120, United States
  • Oklahoma Cancer Specialists
    Tulsa, Oklahoma 74146, United States
  • Charleston Cancer Center
    Charleston, South Carolina 29406, United States
  • Spartanburg Regional-Gibbs Cancer Center
    Spartanburg, South Carolina 29303, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Providence Regional Cancer Partnership
    Everett, Washington 98201, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Universitair Ziekenhuis Antwerpen
    Antwerp, Belgium
  • Centre Hospitalier Jolimont
    La Louvière, Belgium
  • Centre Hospitalier Universitaire de Mons
    Mons, Belgium
  • CFRO Clinique Pasteur
    Brest, France
  • Institut Andrée Dutreix
    Dunkirk, France
  • Clinique Victor Hugo
    Le Mans, France
  • Hôpital de la Croix Rousse
    Lyon, France
  • CROM-Osny
    Osny, France
  • Centre Hospitalier Privé St Grégoire
    Saint-Grégoire, France
  • Institut Català d'Oncologia Badalona
    Badalona, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Institut Català d'Oncologia Girona
    Girona, Spain
  • Hospital Universitario Severo Ochoa
    Leganés, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, Spain
  • Hospital Son Llàtzer
    Palma De Mallorca, Spain
  • Hospital Universitari Son Espases
    Palma De Mallorca, Spain
  • Hospital Clínico Universitario Lozano Blesa
    Zaragoza, Spain
  • Aberdeen Royal Infirmary
    Aberdeen, United Kingdom
  • Edinburgh Cancer Centre
    Edinburgh, United Kingdom
  • Guy's Hospital
    London, United Kingdom
  • Weston Park Hospital
    Sheffield, United Kingdom
09

References and documents

Publications

  • North JR, Takenaka S, Rozek A, Kielczewska A, Opal S, Morici LA, Finlay BB, Schaber CJ, Straube R, Donini O. A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy. J Biotechnol. 2016 May 20;226:24-34. doi: 10.1016/j.jbiotec.2016.03.032. Epub 2016 Mar 23. PubMed 27015977 ↗
  • Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016 Dec 10;239:115-125. doi: 10.1016/j.jbiotec.2016.10.010. Epub 2016 Oct 13. PubMed 27746305 ↗
  • Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotechnol Rep (Amst). 2017 May 17;15:24-26. doi: 10.1016/j.btre.2017.05.002. eCollection 2017 Sep. PubMed 28649557 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jun 2020, 30 months.

Results were first posted in Aug 2022, 2 years 2 months after primary completion.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2017
First posted
Aug 2, 2017
StartActual
Dec 4, 2017
Primary completionActual
Jun 24, 2020
CompletionActual
Jun 24, 2021
Results first posted
Aug 29, 2022
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03237325
Lead sponsor
Soligenix
Responsible party
Sponsor
First posted
Aug 2, 2017
Start date
Dec 4, 2017
Primary completion
Jun 24, 2020
Completion
Jun 24, 2021
Results posted
Aug 29, 2022
Last update
Nov 8, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dusquetide

Start the discussion